Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome

Jake C Robertson; Mustufa A Jafry; Lori Soma; Andrei Shustov; Michi M Shinohara

doi:10.7759/cureus.15482

Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome

Cureus. 2021 Jun 6;13(6):e15482. doi: 10.7759/cureus.15482. eCollection 2021 Jun.

Authors

Jake C Robertson¹, Mustufa A Jafry¹, Lori Soma², Andrei Shustov³, Michi M Shinohara⁴

Affiliations

¹ School of Medicine, University of Washington, Seattle, USA.
² Division of Hematopathology, Department of Pathology, University of Washington, Seattle, USA.
³ Division of Hematology, Department of Medicine, University of Washington, Seattle, USA.
⁴ Division of Dermatology, Department of Medicine, University of Washington, Seattle, USA.

Abstract

Sézary syndrome (SS) is a form of cutaneous T-cell lymphoma (CTCL), demonstrating leukemic involvement of malignant T-cells. Known systemic sequelae of SS include hemophagocytic syndrome-induced anemia, normocytic anemia secondary to bone marrow infiltration, and pancytopenia. We report a patient with SS, initially demonstrating widespread morbilliform eruption, who presented with malignancy-related microangiopathic hemolytic anemia (MAHA). Our findings represent a novel presentation of SS that will inform the differential diagnosis and treatment of future SS patients presenting with anemia and thrombocytopenia.

Keywords: anemia; hemolysis; lymphoma; sézary syndrome; thrombocytopenia.

Publication types

Case Reports